Evidence map›Paper›PMID 38071106›Full record

ArticleVaccine2024

SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy.

Yongjun Sui, Hanne Andersen, Jianping Li, Tanya Hoang, Mahnaz Minai, Bianca M Nagata, Kevin W Bock, Derron A Alves, Mark G Lewis, Jay A Berzofsky

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yongjun SuiVaccine Branch, Center of for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: suiy@mail.nih.gov.
Hanne AndersenBIOQUAL Inc., Rockville, MD 20850, USA.
Jianping LiVaccine Branch, Center of for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Tanya HoangVaccine Branch, Center of for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Mahnaz MinaiInfectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA.
Bianca M NagataInfectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA.
Kevin W BockInfectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA.
Derron A AlvesInfectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA.
Mark G LewisBIOQUAL Inc., Rockville, MD 20850, USA.
Jay A BerzofskyVaccine Branch, Center of for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
National Cancer Institute · USNational Institute of Allergy and Infectious Diseases · USBioqual · US

Funding

Comparative Medicine Infectious Diseases- BethesdaZIGAI001047 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ELKINS, WILLIAM · 2009 to 2025
$535.6M
CCR VB FACS COREZICBC010936 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCKINNON, KATHERINE · 2009 to 2025
$10.9M
Studies of the SARS-CoV-2 Spike ProteinZIABC011941 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BERZOFSKY, JAY A · 2020 to 2025
$6.8M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011941
6 · The paper itself

Abstract

Intranasal mucosal vaccines can more effectively induce mucosal immune responses against SARS-CoV-2. Here, we show in hamsters that an intranasal subunit mucosal vaccine boost with the beta variant S1 can prevent weight loss, in addition to reducing viral load, which cannot be studied in macaques that don't develop COVID-like disease. Protective efficacy against both viral load and weight loss correlated with serum antibody titers. A sex bias was detected in that immune responses and protection against viral load were greater in females than males. We also found that priming with S1 from the Wuhan strain elicited lower humoral immune responses against beta variant and led to less protection against beta viral challenge, suggesting the importance of matched antigens. The greater efficacy of mucosal vaccines in the upper respiratory tract and the need to consider sex differences in vaccine protection are important in the development of future improved COVID-19 vaccines.

Indexed as

COVID-19COVID-19 VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralCricetinaeFemaleHumansMacacaMaleSARS-CoV-2SexismSpike Glycoprotein, CoronavirusWeight LossAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Adjuvanted subunit vaccineImmune correlationIntranasal vaccinationSARS-CoV-2 variantsSex bias

Identifiers

PMID38071106
PMCPMC10843685
OpenAlexW4389478139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.